Please assess the completion status of the following clinical trial:

Trial Title: Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be 18 or older, weigh more than 34kg and may be of either sex and race.~* Subjects must be willing to give informed consent (IC) in writing and be able to do and follow the study. If a subject cannot give informed consent in writing , a legal representative could sign in his place.~* Women of childbearing potential should perform a pregnancy test at the time of entry and accept the use of a medically acceptable contraceptive method during the study.~Exclusion Criteria:~* Creatinine Clearance (CrCl )\<10 mL / min.~* Subjects may not have a history of type I hypersensitivity or idiosyncratic reactions to drugs ganciclovir/valganciclovir~* Pregnancy women.~* Women breast feeding~* Subjects may not present at time of inclusion any clinically significant disease that could interfere with study evaluations.~* Previous participation in another clinical trial sponsored by pharmaceutical industry, in which the promoter and the protocol set which should be the treatment for CMV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.A (Prophylaxis-SPC) (Type: ACTIVE_COMPARATOR): Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
- 1.B (Prophylaxis- PK model) (Type: EXPERIMENTAL): Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
- 2.A (Treatment-SPC) (Type: ACTIVE_COMPARATOR): Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
- 2.B (Treatment-PK model) (Type: EXPERIMENTAL): Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model

Based on this trial design, predict the completion outcome and termination type (if applicable).